<DOC>
	<DOCNO>NCT01868451</DOCNO>
	<brief_summary>The purpose study compare outcome across 4 different treatment group . The investigator hope treatment improve ability cure patient HL also limit long-term side effect treatment . Although eliminate radiation cohort 4 eliminate risk long-term side effect radiation , also possible BV+AVD chemotherapy alone may increase risk Hodgkin lymphoma come back initial treatment .</brief_summary>
	<brief_title>Brentuximab Vedotin Combined With AVD Chemotherapy Patients With Newly Diagnosed Early Stage , Unfavorable Risk Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologic diagnosis classical , CD30 positive Hodgkin lymphoma confirm enrol institution FDGavid disease FDGPET/CT measurable disease least 1.5 cm CT Ann Arbor Stage I II disease Disease bulk define lymph node mass transverse maximal diameter &gt; 7.0 cm OR coronal maximal diameter &gt; 7.0 cm CT imaging Females childbearing age must acceptable form birth control per institutional standard Age 18 60 Cardiac ejection fraction ≤ 50 % Hemoglobinadjusted diffusing capacity carbon monoxide &lt; 40 % ANC≤1000/μl Platelets≤75,000/μl Total bilirubin ≥ 2.0 mg/dl absence history Gilbert 's disease Serum creatinine clearance &lt; 30 mL/min estimate CockcroftGault Method Known pregnancy breastfeed Medical illness unrelated Hodgkin Lymphoma , , opinion attend physician and/or MSKCC principal investigator , make participation study inappropriate . Peripheral neuropathy &gt; grade 1 Patients receive chronic treatment systemic steroid . However , patient receive 10 day steroid therapy prior start treatment BV+AVD .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>DACARBAZINE</keyword>
	<keyword>DOXORUBICIN/ADRIAMYCIN</keyword>
	<keyword>SGN-35 ( BRENTUXIMAB VEDOTIN )</keyword>
	<keyword>VINBLASTINE</keyword>
	<keyword>Involved-site radiation therapy ( ISRT )</keyword>
	<keyword>Early stage</keyword>
	<keyword>13-034</keyword>
</DOC>